JP2004529158A5 - - Google Patents

Download PDF

Info

Publication number
JP2004529158A5
JP2004529158A5 JP2002584967A JP2002584967A JP2004529158A5 JP 2004529158 A5 JP2004529158 A5 JP 2004529158A5 JP 2002584967 A JP2002584967 A JP 2002584967A JP 2002584967 A JP2002584967 A JP 2002584967A JP 2004529158 A5 JP2004529158 A5 JP 2004529158A5
Authority
JP
Japan
Prior art keywords
hsv
individual
pharmaceutical composition
carrying
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002584967A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004529158A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2002/000345 external-priority patent/WO2002087625A1/en
Publication of JP2004529158A publication Critical patent/JP2004529158A/ja
Publication of JP2004529158A5 publication Critical patent/JP2004529158A5/ja
Pending legal-status Critical Current

Links

JP2002584967A 2001-05-02 2002-05-02 混成殺腫瘍ヘルペスウイルスベクター Pending JP2004529158A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28771701P 2001-05-02 2001-05-02
PCT/IL2002/000345 WO2002087625A1 (en) 2001-05-02 2002-05-02 Composite oncolytic herpes virus vectors

Publications (2)

Publication Number Publication Date
JP2004529158A JP2004529158A (ja) 2004-09-24
JP2004529158A5 true JP2004529158A5 (https=) 2005-12-22

Family

ID=23104029

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002584967A Pending JP2004529158A (ja) 2001-05-02 2002-05-02 混成殺腫瘍ヘルペスウイルスベクター

Country Status (3)

Country Link
EP (1) EP1406668A1 (https=)
JP (1) JP2004529158A (https=)
WO (1) WO2002087625A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US20030027322A1 (en) 2000-11-29 2003-02-06 Federoff Howard J. Helper virus-free herpesvirus amplicon particles and uses thereof
US8092791B2 (en) 2001-05-23 2012-01-10 University Of Rochester Method of producing herpes simplex virus amplicons, resulting amplicons, and their use
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US20060239970A1 (en) * 2003-01-23 2006-10-26 Federoff Howard J Herpesvirus amplicon particles
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379674B1 (en) * 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
GB9816781D0 (en) * 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
US6774119B1 (en) * 1999-04-26 2004-08-10 Cedars-Sinai Medical Center Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells

Similar Documents

Publication Publication Date Title
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
CN1094642A (zh) 治疗组合物
JP2005506957A (ja) ウイルス性、増殖性および炎症性の疾患の治療のためにビタミンｂ１２およびインターフェロンを用いた複合治療
JP2009504157A5 (https=)
JP2004509061A5 (https=)
RU2007105354A (ru) Применение комбинации циклоспорина и пэгилированного интерферона для лечения гепатита с (hcv)
JP2005533021A5 (https=)
WO2008024843A3 (en) Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein
RU2012136824A (ru) Способы лечения вирусной инфекции гепатита с
CN102083435A (zh) 特拉匹韦给药方案
MA27699A1 (fr) Vaccin contre vhc
JP2004529158A5 (https=)
AR022116A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
EA200900558A1 (ru) Композиции аполактоферрина и способы их применения в лечении вирусного гепатита с
JP2007501806A5 (https=)
RU2013120345A (ru) Новые способы лечения инфекции, вызванной вирусом гепатита с
Larrey et al. 1054 safety, pharmacokinetics and antiviral effect of BI 207127, a novel HCV RNA polymerase inhibitor, after 5 days oral treatment in patients with chronic hepatitis C
CN103096885A (zh) 不饱和脂肪酸用于抑制病毒复制和/或感染的用途
Jo et al. Early experience of oncolytic virus injection combined with sorafenib in a patient with advanced hepatocellular carcinoma and portal vein thrombosis
JP2005502585A5 (https=)
JP2017514834A5 (https=)
Frank et al. Outbreak of hepatitis B virus infection in an ambulatory haemodialysis clinic in Germany
Flisiak et al. Effect of lamivudine treatment on plasma levels of transforming growth factor beta 1, tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B
WO2026052081A1 (zh) 用于治疗乙型肝炎的药物及组合
TWI601531B (zh) Ｎ－第三丁氧基羰基－３－甲基－ｌ－纈胺醯基－（４ｒ）－ｎ－（（１ｒ，２ｓ）－１－｛［（環丙基磺醯基）胺基］羰基｝－２－乙烯基環丙基）－４－［（４－甲氧基－７－氯異喹啉－１－基）氧］－ｌ－脯氨醯胺之用途